Shockwaves and fibrosis signaling in human tissue: a 2024 systematic review · Lab study · 2024
How does shockwave affect scar and fibrosis signals in human tissue?
This review looked at 29 studies of human scar and fibrotic tissue, mostly cells grown in the lab from patient samples. Shockwave changed signals linked to inflammation, new blood vessels and collagen, often depending on energy and timing, sometimes in opposite directions. It did not look at whether scars improved.
Explores how shockwave works- studies of human scar or fibrotic tissue
- 29
- randomised trial among them
- 1
- year published
- 2024
Good to know: Most changes were measured within the first three days.
Demuynck L, Moonen S, Thiessen F, et al. Int J Mol Sci, 2024 · Read the paper ↗
The treatment
- Energy and regimens in included studies
- Text: energy flux density 0.0024–0.32 mJ/mm², 3–5 Hz, 150–3,000 pulses (a later paragraph gives 250–5,000 pulses). Table 3 is broader: 1–50 Hz, and one study (skin and fat in obesity) with 4,000 shots at 180 mJ plus 2,000 at 100 mJ through two tips, reported in mJ rather than mJ/mm². Single exposures of cells, up to 10 sessions in patients (for example 2 sessions a week in the hand-scar trial). Focused, defocused, radial, piezoelectric and cardiac devices were used.
- Authors' energy recommendation (opinion)
- The Discussion recommends an energy flux density between 0.0024 and 0.32 mJ/mm²: values as low as 0.0024 mJ/mm² for inflammation and proliferation, 0.11–0.30 mJ/mm² for differentiation and apoptosis (Figure 3). This comes from comparing different studies, cells and devices; it was not tested as a dose–response in patients.
- Comparators in included studies
- Untreated cells or tissue, the contralateral untreated side, sham treatment, healthy tissue or the pre-treatment state; one keloid study (22 shockwave, 17 steroid) and one chondrocyte study with hyaluronic acid and platelet-rich plasma groups.
Who took part
Cells grown from human scars, keloids, ulcers and other fibrotic tissue, plus a few patient groups with biopsies or blood tests.
Side effects
One keloid study mentions isolated minor reactions: redness, small skin bleeds and swelling.
All the numbers and the full appraisal
What the full paper reports.
No new patient cohort. Twenty-nine studies of human fibrotic tissue (one randomized trial, 28 non-randomized), mostly cells grown from patient samples, plus some small patient groups with biopsies or blood tests: skin or systemic fibrosis 12 (scars, keloids, chronic ulcers, obesity, systemic sclerosis), bone 8, heart 3, muscle and tendon 3, and lung, prostate and immune cells 1 each. Table 3 lists 3 to 75 participants or samples per study.
Evidence base and certainty1 reported outcome
Evidence base and certainty
Qualitative finding
143 studies met the criteria (29 human, 114 animal); only the 29 human studies were analysed: one randomized trial and 28 non-randomized, mostly in vitro work on cells from fibrotic samples, with some small patient studies. Outcome-level risk of bias was low for 44 outcomes, some concerns for 3 and serious for 11, mainly because of how outcomes were measured. GRADE certainty was low or very low for all 36 outcomes in Table 4.
Analysis details and source
Counts as reported in the PRISMA flowchart and Sections 3.1–3.3; the animal studies are not described further.
Inflammation and immune cells1 reported outcome
Inflammation and immune cells
Qualitative finding
Chronic venous ulcers (9 patients, before and after): CD68 lower and the M2 macrophage marker CD163 generally higher (60% of patients); TNF, IL-1, PDGF and TGF-β higher at 150 pulses, IL-6 and VEGF unchanged. Skin and fat of 14 women with obesity (treated versus untreated side): COX-2, T and B lymphocytes and NK cells higher. Osteoarthritic chondrocytes in vitro: TNF-α and IL-17A lower, IL-10 higher. Bronchial fibroblasts (3 COPD, 3 control): NF-κB-p65 lower. The review summarizes this as suppression of inflammation, although several pro-inflammatory markers rose.
Analysis details and source
Single small studies, mostly before–after or treated-versus-untreated tissue; marker changes, not clinical inflammation.
Collagen and extracellular matrix1 reported outcome
Collagen and extracellular matrix
Qualitative finding
Collagen I was lower in myofibroblasts from fat tissue in vitro, in keloids (39 patients: 22 shockwave, 17 steroid; staining 6 to 48 weeks after treatment), in fibroblasts from burn scars and in prostate cancer–associated fibroblasts; collagen III was lower in keloids. Collagen I (COL1A1, COL-I α1) rose in thoracolumbar fascia fibroblasts and in anterior cruciate ligament remnant cells. For the only randomized study (retracting hand scars, N = 70) Table 3 reports replacement of type III with type I collagen, while the Discussion states that shockwaves replace type I with type III. Collagen II showed no difference in one study and an increase in another. In fibroblasts from burn scars (N = 4) fibronectin mRNA fell while the protein rose.
Analysis details and source
Directions copied from Tables 3 and 5; the contradiction about the hand-scar trial is left unresolved. The text also says the collagen I decrease in two studies was not significant, while Table 3 marks both as significant.
Blood-vessel signals1 reported outcome
Blood-vessel signals
Qualitative finding
VEGF, VEGF-A or VEGFR-2 rose in several studies (chronic leg-ulcer cells, obese skin, marrow cells from femoral-head osteonecrosis, heart cells, patients with ischaemic heart failure), and CD31 rose in chronic ulcers, pressure ulcers and hand scars; CD34 did not differ in two studies but rose in the hand-scar trial. In systemic sclerosis (30 patients, before and after, 30 and 60 days) VEGF, vWF, ICAM-1, MCP-1 and circulating endothelial and progenitor cells rose, fibrosis markers did not change significantly, and nitric oxide rose in "2/3" of patients without significance.
Analysis details and source
Marker changes in tissue, cells or blood; none of these studies measured clinical healing within this review.
Energy- and time-dependent cell responses1 reported outcome
Energy- and time-dependent cell responses
Qualitative finding
In keratinocytes from hypertrophic scars, 0.1 mJ/mm² left p21, p27 and Notch1 unchanged, whereas 0.2–0.3 mJ/mm² raised them at 24 hours and lowered them at 72 hours. In bone-marrow stromal cells, 0.2 mJ/mm² raised Ki67 at 6 and 12 hours and lowered caspase-3, while 0.3 mJ/mm² lowered Ki67 at 12 hours and raised caspase-3. Ki67 did not change in another study.
Analysis details and source
Single in vitro experiments; they show that responses can reverse with dose and time, not which dose helps patients.
How treatment was delivered
Text: energy flux density 0.0024–0.32 mJ/mm², 3–5 Hz, 150–3,000 pulses (a later paragraph gives 250–5,000 pulses). Table 3 is broader: 1–50 Hz, and one study (skin and fat in obesity) with 4,000 shots at 180 mJ plus 2,000 at 100 mJ through two tips, reported in mJ rather than mJ/mm². Single exposures of cells, up to 10 sessions in patients (for example 2 sessions a week in the hand-scar trial). Focused, defocused, radial, piezoelectric and cardiac devices were used.
The Discussion recommends an energy flux density between 0.0024 and 0.32 mJ/mm²: values as low as 0.0024 mJ/mm² for inflammation and proliferation, 0.11–0.30 mJ/mm² for differentiation and apoptosis (Figure 3). This comes from comparing different studies, cells and devices; it was not tested as a dose–response in patients.
Untreated cells or tissue, the contralateral untreated side, sham treatment, healthy tissue or the pre-treatment state; one keloid study (22 shockwave, 17 steroid) and one chondrocyte study with hyaluronic acid and platelet-rich plasma groups.
The review did not collect adverse events: visible or clinical changes were an exclusion criterion. Its conclusion mentions isolated minor reactions (erythema, petechiae, oedema) from one keloid study and calls shockwave therapy safe, without event counts.
Author-reported: only one randomized trial; nearly all studies lacked baseline or follow-up assessments and most looked only at the first 72 hours; in vitro set-ups such as a liquid–air interface may alter shockwave reflection; populations and endpoints varied; analysing human studies separately from animal studies narrowed the results.
Certainty: outcome-level risk of bias was serious for 11 outcomes and of some concern for 3, mainly from outcome measurement; GRADE was low or very low for every outcome, and many outcomes rest on one study. Blinding of researchers was usually not possible.
Internal inconsistencies: the text gives 5 to 75 people per study, but Table 3 lists studies with N = 3 and N = 4; the text gives 3–5 Hz and 150–3,000 pulses, but Table 3 includes 1–50 Hz and one study with 6,000 shots over two tips, and a later paragraph gives 250–5,000 pulses; the Discussion says shockwaves replace collagen I with collagen III, while Tables 3 and 5 report the reverse for the hand-scar trial; the text calls two collagen I decreases non-significant that Table 3 marks as significant; the keloid study is labelled both non-randomized and randomized.
Extractor: many in-text citations do not match the reference list. Table 3 cites reference 22, a rat radiation-cystitis study, for human bone-marrow stromal cells; the text cites reference 28 (tenocytes) for T-cells, reference 40 (a stroke neurogenesis review) for fetal osteoblastic cells, reference 15 (a commentary on in vitro systems) and references 34 and 35 (risk-of-bias tools) for findings, and references 1, 41 and 43–46 (animal studies, one of which also reports a bladder clinical trial; none is among the 29 included studies) as evidence in a human-only synthesis. Individual claims therefore cannot be reliably traced to their source.
Extractor: the abstract and conclusions go beyond the data, describing beneficial effects on fibrosis, a safe treatment that favourably impacts clinical outcomes and demonstrated safety, although clinical outcomes were excluded and harms were not collected; the energy recommendation is a cross-study inference. Funding: University of Antwerp. Conflicts: none declared; no device-maker ties are reported. The supplements were not read.
Findings checked against the full source by a separate automated reviewer.
Limitations noted by the reviewers
- Author-reported: only one randomized trial; nearly all studies lacked baseline or follow-up assessments and most looked only at the first 72 hours; in vitro set-ups such as a liquid–air interface may alter shockwave reflection; populations and endpoints varied; analysing human studies separately from animal studies narrowed the results.
- Certainty: outcome-level risk of bias was serious for 11 outcomes and of some concern for 3, mainly from outcome measurement; GRADE was low or very low for every outcome, and many outcomes rest on one study. Blinding of researchers was usually not possible.
- Internal inconsistencies: the text gives 5 to 75 people per study, but Table 3 lists studies with N = 3 and N = 4; the text gives 3–5 Hz and 150–3,000 pulses, but Table 3 includes 1–50 Hz and one study with 6,000 shots over two tips, and a later paragraph gives 250–5,000 pulses; the Discussion says shockwaves replace collagen I with collagen III, while Tables 3 and 5 report the reverse for the hand-scar trial; the text calls two collagen I decreases non-significant that Table 3 marks as significant; the keloid study is labelled both non-randomized and randomized.
- Extractor: many in-text citations do not match the reference list. Table 3 cites reference 22, a rat radiation-cystitis study, for human bone-marrow stromal cells; the text cites reference 28 (tenocytes) for T-cells, reference 40 (a stroke neurogenesis review) for fetal osteoblastic cells, reference 15 (a commentary on in vitro systems) and references 34 and 35 (risk-of-bias tools) for findings, and references 1, 41 and 43–46 (animal studies, one of which also reports a bladder clinical trial; none is among the 29 included studies) as evidence in a human-only synthesis. Individual claims therefore cannot be reliably traced to their source.
- Extractor: the abstract and conclusions go beyond the data, describing beneficial effects on fibrosis, a safe treatment that favourably impacts clinical outcomes and demonstrated safety, although clinical outcomes were excluded and harms were not collected; the energy recommendation is a cross-study inference. Funding: University of Antwerp. Conflicts: none declared; no device-maker ties are reported. The supplements were not read.
Source-linked critical reading
Systematic review of mechanistic studies in human tissue
Technical source record
Complete local PDF read (36 pages), including all sections, Tables 1–5 with every continuation page, Figures 1–4, funding, conflict statement and all 57 references. Supplementary Materials S1–S2 were not available locally and were not read.
Laboratory studies on human scar and fibrotic tissue, mostly cells grown in dishes plus a few small patient groups, suggest shockwaves can change signals involved in inflammation, new blood vessels and collagen. The changes often differed with energy and timing and were rated low or very low certainty. This research does not show that shockwave therapy softens scars or treats fibrosis in patients.
Which cells, molecules and signaling pathways does shockwave therapy change in human fibrotic tissue, and do the changes depend on energy and frequency?
Systematic review registered on PROSPERO (CRD42023404145) and reported following PRISMA 2020. PubMed, Web of Science, Embase and Cochrane were searched in September–October 2022 and again from December 2023 to February 2024; two reviewers screened and extracted, risk of bias was rated with ROB-II or ROBINS-I and certainty with GRADE. Of 143 eligible studies (29 human, 114 animal), only the 29 human studies were analysed; there was no meta-analysis.
No new patient cohort. Twenty-nine studies of human fibrotic tissue (one randomized trial, 28 non-randomized), mostly cells grown from patient samples, plus some small patient groups with biopsies or blood tests: skin or systemic fibrosis 12 (scars, keloids, chronic ulcers, obesity, systemic sclerosis), bone 8, heart 3, muscle and tendon 3, and lung, prostate and immune cells 1 each. Table 3 lists 3 to 75 participants or samples per study.
Any form of shockwave applied to fibrotic human tissue or cells. The text gives an energy flux density of 0.0024–0.32 mJ/mm², 3–5 Hz and 150–3,000 pulses, but Table 3 also lists 1–50 Hz, one study with 4,000 plus 2,000 shots through two different tips, and energy reported only in mJ for that study. Regimens ranged from a single exposure of cultured cells to up to 10 sessions in patients.
The review set no comparator. Included studies compared treated with untreated cells or tissue, the untreated side, sham or the pre-treatment state (before and after in one group); one keloid study had a steroid-injection group and one chondrocyte study also tested hyaluronic acid and platelet-rich plasma.
Cell and molecular markers only: immune cells and cytokines, growth factors, blood-vessel markers, collagen types, and markers of cell growth, differentiation and death, measured by staining, PCR, western blot, ELISA or flow cytometry. Visible or clinical changes were an exclusion criterion. Most studies measured within 72 hours of treatment; a few patient studies followed up to 60 days or 48 weeks.
In mostly laboratory studies, shockwaves changed markers of inflammation (macrophage types, cytokines), blood-vessel formation (VEGF, CD31), collagen (type I lower in four studies and higher in three; type III lower in keloids) and cell growth and death, often depending on energy and timing; several markers moved in opposite directions between studies, and a systemic sclerosis study found no significant change in fibrosis markers. Certainty was rated low or very low for every outcome, and most studies measured only within the first 72 hours.
The review did not collect adverse events: visible or clinical changes were an exclusion criterion. Its conclusion mentions isolated minor reactions (erythema, petechiae, oedema) from one keloid study and calls shockwave therapy safe, without event counts.
Only human-tissue studies were analysed; nearly all were non-randomized, small and short-term, many outcomes rest on a single study, and GRADE certainty was low or very low throughout. The paper has internal errors: several in-text citations point to animal studies or methods papers, the Discussion reverses the collagen change reported in Table 3 for the one randomized study, and the stated ranges for sample size, frequency and pulses do not match Table 3. The conclusions call shockwave therapy safe and say it improves clinical outcomes, which this review, having excluded clinical outcomes and not collected harms, did not assess. Funded by the University of Antwerp; no conflicts declared.
Background on candidate biological pathways for people studying scars and fibrosis. It cannot set a dose, tell a patient whether a scar will improve, or show that treatment is safe, because clinical outcomes and harms were not collected.
Controlled studies in patients with baseline measurements and longer follow-up, clearly reported device type and calibration, and biological markers linked to blinded clinical scar or fibrosis outcomes and to recorded harms.
Read the original article.
Systematic Review on Working Mechanisms of Signaling Pathways in Fibrosis During Shockwave Therapy.
Demuynck L, Moonen S, Thiessen F, Vrints I, Moortgat P, Meirte J, van Breda E, Van Daele U. · Int J Mol Sci · 2024
Open the publication record or available full-text files.
Checked against the full paper · Clinical review: Dr. Marcus Yu Bin Pai, · How we review →